Sugi Predict

Sugi Predict / Compounds / SCHEMBL851862

SCHEMBL851862

SCHEMBL851862

CCOC(=O)c1cc(Cl)nc(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.58
▸ CA1 P00915 3/20 0.58
▸ CA2 P00918 3/20 0.58
▸ CA7 P43166 3/20 0.58
▸ CA9 Q16790 3/20 0.58
▸ CA14 Q9ULX7 3/20 0.58
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ ALDH1A1 P00352 2/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ ESR1 P03372 1/20 0.48
▸ ESR2 Q92731 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ CYP1A2 P05177 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ MAOA P21397 1/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ BCL2L1 Q07817 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1179728 0.91 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL8974754 0.90 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL2532558 0.88 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL15321600 0.88 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL17053329 0.88 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL29965908 0.88 CA12 (0.50) CA12CA1CA2CA7CA9
SCHEMBL1179421 0.87 SMN1; SMN2 (0.55) CA12CA1CA2CA7CA9
SCHEMBL1314039 0.87 GPR119 (0.49) CA12CA1CA2CA7CA9
SCHEMBL1424925 0.84 KMT2A (0.46) CA12CA1CA2CA7CA9
SCHEMBL6121134 0.84 ATF1 (0.47) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0268775-B1 METHOD FOR PROTECTING PLANTS AGAINST DISEASES CIBA-GEIGY AG (CH) 1992-12-23 — — EP claimed
US-4968344-A FUNGICIDES, BACTERICIDES CIBA-GEIGY CORPORATION (US) 1990-11-06 — — US claimed
EP-0268775-A1 Method for protecting plants against diseases CIBA-GEIGY AG (CH) 1988-06-01 — — EP claimed
CN-87106598-A Protective plant is avoided the method for disease — 1988-05-04 — — CN claimed
EP-4680607-A1 BICYCLIC UREAS AS KINASE INHIBITORS Incyte Corporation (US) 2026-01-21 — — EP disclosed
US-20250304580-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2025-10-02 — — US disclosed
US-20250042897-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2025-02-06 — — US disclosed
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 — — US disclosed
US-20240317744-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORPORATION 2024-09-26 — — US disclosed
WO-2024191996-A1 BICYCLIC UREAS AS KINASE INHIBITORS INCYTE CORPORATION (US) 2024-09-19 — — WO disclosed
EP-4430029-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE Vigil Neuroscience, Inc. (US) 2024-09-18 — — EP disclosed
US-20240217964-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS NEWAVE PHARMACEUTICAL INC. 2024-07-04 — — US disclosed
EP-0369762-B1 Pesticides ROUSSEL UCLAF (FR) 1993-12-29 — — EP disclosed
US-5202356-A Insecticides, miticides THE WELLCOME FOUNDATION LIMITED (GB) 1993-04-13 — — US disclosed
EP-0268775-B1 METHOD FOR PROTECTING PLANTS AGAINST DISEASES CIBA-GEIGY AG (CH) 1992-12-23 — — EP disclosed
US-4968344-A FUNGICIDES, BACTERICIDES CIBA-GEIGY CORPORATION (US) 1990-11-06 — — US disclosed
CN-1045576-A Pesticide WELLCOME FOUND (GB) 1990-09-26 — — CN disclosed
EP-0369762-A1 Pesticides ROUSSEL-UCLAF (FR) 1990-05-23 — — EP disclosed
EP-0268775-A1 Method for protecting plants against diseases CIBA-GEIGY AG (CH) 1988-06-01 — — EP disclosed
CN-87106598-A Protective plant is avoided the method for disease — 1988-05-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304580-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE MSR1, FPR2, CD14 CA12 2937/4885CA1 3334/4885CA2 3043/4885
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 CA12 4119/4885CA1 3633/4885CA2 587/4885
US-20240217964-A1 QUINUCLIDINONE ANALOGUES AS ANTICANCER AGENTS NQO2, PRMT1, PRMT7 CA12 3906/4885CA1 3502/4885CA2 4171/4885
US-20240317744-A1 Bicyclic Ureas As Kinase Inhibitors JAK2, UCK2, ULK2 CA12 4580/4885CA1 4241/4885CA2 3707/4885
US-20250042897-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE MSR1, FPR2, CD14 CA12 2611/4885CA1 3157/4885CA2 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.